Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Colorectal Cancer Clinical Trial

Official title:

A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00503685
• Other study ID #: 13936
• Secondary ID: CP02-0657CP13-06
• Status: Completed
• Phase: Phase 2
• Start date: June 2007
• Est. completion date: March 2009

Study information

• Verified date: May 2018
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Participants with metastatic Colorectal Cancer (mCRC) who have progressed on a prior Anti-epidermal growth factor receptor (EGFR) regimen randomized to receive IMC-A12 monotherapy or combination therapy with cetuximab to assess response, survival, durations of response, safety and tolerability as well as pharmacodynamics of IMC-A12 and cetuximab

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• The participant has histologically or cytologically-confirmed colorectal cancer with metastatic disease documented on diagnostic imaging studies

• The participant has measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded), measuring = 2 centimeter (cm) on conventional measurement techniques or = 1 cm on spiral computed tomography (CT) scan

• The participant has clinical documentation of disease progression during treatment or within 6 weeks after receiving the last dose of a therapeutic regimen for metastatic disease containing an anti-EGFR-component (cetuximab or panitumumab). Toxicity or planned treatment break will not be regarded as adequate evidence of disease progression and such participants will not be eligible for this trial

• The participant has received at least one prior standard and/or investigational regimen for metastatic disease

• The participant is age = 18 years

• The participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1 (Karnofsky = 80%

• The participant has adequate hematologic function as defined by an absolute neutrophil count = 1500/microliter (µL), hemoglobin = 9 grams/deciliter (g/dL), and a platelet count = 100,000/µL

• The participant has adequate hepatic function as defined by a total bilirubin = 1.5 x the upper limit of normal (ULN), and aspartate transaminase (AST) and alanine transaminase (ALT) = 3 x the ULN (or = 5 x the ULN in the presence of known liver metastases)

• The participant has adequate coagulation function as defined by international normalized ratio (INR) = 1.5 and partial thromboplastin time (PTT) = 1.5 x the ULN. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin, and if on warfarin must have an INR between 2 and 3 and have no active bleeding or pathological condition that carries a high risk of bleeding (for example, tumor involving major vessels or invading the rectal lumen, or known varices)

• The participant has adequate renal function as defined by serum creatinine = 1.5 x the institutional ULN or creatinine clearance = 60 milliliters/minute (mL/min) for participants with creatinine levels above the ULN, as well as urine protein = 1+ on urine dipstick or routine urinalysis [(UA), if urine dipstick/routine UA indicates = 2+ protein, a 24-hour urine collection for protein must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study]

• The participant has fasting serum glucose < 120 milligrams/deciliter (mg/dL) or below the ULN

• The participant has a life expectancy of > 3 months

• Because the teratogenicity of IMC-A12 (cixutumumab) is not known, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

• The participant has the ability to understand and the willingness to sign a written informed consent document

• The participant has a tumor that is K-ras wild-type (absence of mutations at codon 12 or 13, as determined by the DxS K-ras Mutation Kit [polymerase chain reaction (PCR)-based analysis]).

• The participant experienced either a confirmed partial response or stable disease of = 24 weeks duration during prior treatment with a cetuximab- or panitumumab-containing regimen except for participants with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) promoter polymorphism, for example, Gilbert syndrome, confirmed by genotyping or Invader®UGT1A1 Molecular Assay prior to enrollment. Participants enrolled with Gilbert Syndrome must have a total bilirubin = 3 x ULN. If the participant has liver metastases, total bilirubin must be = 3 x ULN.

Exclusion Criteria

• The participant has received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or has not recovered from adverse events due to agents administered more than 4 weeks earlier. Neurotoxicity, if present, must have recovered to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 3.0 grade = 2.

• The participant is receiving any other investigational agent(s).

• The participant has a history of treatment with other agents targeting the insulin-like growth factor receptor (IGFR).

• The participant has known brain or leptomeningeal metastases.

• The participant has a history of primary central nervous system tumors, seizures not well controlled with standard medical therapy, or history of stroke within 6 months prior to randomization.

• The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or IMC-A12 (cixutumumab).

• The participant has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting glucose < 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition.

• The participant has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• The participant is pregnant or lactating.

• The participant is known to be positive for infection with the human immunodeficiency virus.

• The participant is receiving therapy with immune modulators such as cyclosporine or tacrolimus.

• The participant has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in-situ; or c) other primary solid tumor curatively resected treated with no known active disease present and no treatment administered for the last 3 years.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Disease Progression

Intervention

Biological:
• IMC-A12
10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
• cetuximab
Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.

Locations

Country	Name	City	State
United States	ImClone Investigational Site	Buffalo	New York
United States	ImClone Investigational Site	Los Angeles	California
United States	ImClone Investigational Site	New Haven	Connecticut
United States	ImClone Investigational Site	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)]	ORR is the percentage of participants with a confirmed CR or PR, as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is the disappearance of all target and non-target lesions; PR is a =30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions. ORR is calculated as a total number of participants with CR or PR from start of the treatment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.	Start of randomization/treatment to date of objective progressive disease (PD) up to 28.3 weeks
Secondary	Progression-Free Survival (PFS)	PFS was defined as the duration from the date of randomization/treatment to the date of PD or death from any cause. PD was determined using RECIST criteria version 1.0. PD is =20% increase in sum of longest diameter of target lesions or the appearance of new lesions. Participants who had no PD or death at the time of the data inclusion cutoff, PFS was censored at their last tumor assessment prior to the cutoff date. Participants who began a new antitumor treatment before evidence of PD were categorized as PD.	Randomization/treatment to measured PD up to 28.3 weeks
Secondary	Overall Survival (OS)	OS is defined as the duration from the date of randomization/treatment to the date of death from any cause. Participants who were alive at the time of the data inclusion cutoff, OS was censored at the last date the participant was known to be alive.	Randomization/treatment to date of death from any cause up to 26.9 months
Secondary	Duration of Stable Disease (SD)	The duration of SD is measured from the date of randomization/treatment until the date of PD. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. RECIST criteria version 1.0 was used to asses PR and PD. PR is =30% decrease in sum of longest diameter of target lesions. PD is =20% increase in sum of longest diameter of target lesions and/or a new lesion. Participants who had no PD or death at the time of the data inclusion cutoff, duration of SD was censored at their last tumor assessment prior to the cutoff date.	Time from randomization/treatment to first date of PD up to 28.3 weeks
Secondary	Duration of Overall Response	The duration of overall response (CR or PR) was defined as the time from first objective status assessment of CR or PR to the first time of PD or death due to any cause. CR, PR and PD were determined using RECIST criteria version 1.0. CR is the disappearance of all target and non-target lesions; PR is a =30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; PD is =20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants with CR or PR who had no PD or death at the time of the data inclusion cutoff, the duration of overall response was censored at their last tumor assessment prior to the cutoff date. Duration of overall response was not analyzed due to low number of participants with CR or PR.	Time of response to time of measured PD or death up to 161 days
Secondary	Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)	Data presented are the number of participants who experienced nonserious adverse events (AEs) during the study including the 30-day follow-up. A summary of serious AEs (SAEs) and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.	Randomization/treatment up to 26.9 months
Secondary	Number of Participants Reporting Treatment-Emergent Severe Adverse Events	Data presented are the number of participants who experienced serious adverse events (SAEs) or death during the study including the 30-day follow-up. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.	Randomization/treatment up to 26.9 months
Secondary	Maximum Concentration (Cmax)		Week 1 (Initial dose), Week 3 (Dose 2), Week 5 (Dose 3), Week 7 (Dose 4), Week 9 (Dose 5), and Week 11 (Dose 6)
Secondary	Minimum Concentration (Cmin)		Week 1 (Initial dose), Week 3 (Dose 2), Week 5 (Dose 3), Week 7 (Dose 4), Week 9 (Dose 5), and Week 11 (Dose 6)
Secondary	Area Under Serum Concentration (AUC)		Week 1 (Initial dose), Week 3 (Dose 2), Week 5 (Dose 3), Week 7 (Dose 4), Week 9 (Dose 5), and Week 11 (Dose 6)
Secondary	Percentage of Participants With Complete Response (CR) or Partial Response (PR, Response Rate) in Participants With Kirsten Rat Sarcoma (K-ras) Mutations	The response rate in participants with K-ras mutations was not collected for analysis.	Treatment up to 26.9 months
Secondary	Expression of Type I Insulin-Like Growth Factor Receptors (IGF-IR)		Randomization/treatment up to 26.9 months
Secondary	Expression of IGF Binding Proteins (IGFBP2, IGFBP3)		Randomization/treatment up to 26.9 months